GLP‑1 Medication Side Effects
Detailed information on serious side effects associated with Ozempic, Wegovy, and other GLP-1 receptor agonists, and their connection to legal claims in Canada.
What Side Effects Are Associated with GLP-1 Medications?
GLP-1 receptor agonists — including Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza — are among the most widely prescribed medications in Canada. While many patients tolerate them well, a significant number have reported serious adverse events, some of which are now the subject of legal proceedings.
This page summarizes the most clinically significant side effects that have been linked to GLP-1 medications and that are relevant to current Canadian legal inquiries. This is for informational purposes only and does not constitute medical or legal advice.
Gastroparesis (Stomach Paralysis)
Gastroparesis is a condition in which the stomach cannot empty itself of food normally. The muscles that move food through the digestive tract stop working properly, causing food to remain in the stomach much longer than it should.
Common Symptoms
- Nausea, sometimes severe and persistent
- Vomiting, including undigested food eaten hours earlier
- Abdominal bloating and pain
- Feeling full quickly, even after small meals
- Acid reflux and heartburn
- Unexplained weight loss and malnutrition
- Blood sugar fluctuations (especially in people with diabetes)
Connection to GLP-1 Medications
GLP-1 medications slow gastric emptying as part of their mechanism of action. Research and regulatory communications have linked GLP-1 receptor agonists to gastroparesis in some patients, including cases where symptoms persisted after stopping the medication.
Health Canada has issued communications regarding the association between GLP-1 medications and gastrointestinal adverse events. Product monograph updates have been made for several GLP-1 drugs to reflect this emerging information.
Bowel Obstruction and Ileus
A bowel obstruction occurs when the small or large intestine is partially or fully blocked, preventing the normal passage of food, fluid, and gas. Ileus is a related condition involving a temporary halt in intestinal movement without a physical blockage.
Common Symptoms
- Severe abdominal cramping and pain
- Inability to pass stool or gas
- Abdominal swelling and distension
- Nausea and vomiting
- Loss of appetite
Connection to GLP-1 Medications
Reports of ileus and bowel obstruction have been identified in post-marketing surveillance of GLP-1 receptor agonists. Regulatory agencies and researchers have noted these events in connection with drugs including semaglutide.
Bowel obstruction can be life-threatening and may require emergency surgery. Patients who were hospitalized or required surgical intervention for bowel obstruction while taking a GLP-1 medication may have a qualifying legal claim.
Vision Loss (NAION)
Non-arteritic anterior ischemic optic neuropathy (NAION) is a condition in which blood flow to the optic nerve is reduced, causing sudden, painless vision loss. It is a leading cause of acute optic nerve damage in adults over 50.
Common Symptoms
- Sudden painless vision loss, often noticed upon waking
- Blurred or darkened vision in one eye
- Loss of peripheral or central vision
- Vision that does not improve after initial loss
Connection to GLP-1 Medications
A 2024 study published in JAMA Ophthalmology reported that patients taking semaglutide had a significantly higher risk of developing NAION compared to patients taking other diabetes or weight-loss medications. This research has prompted significant interest in the legal community.
NAION-related vision loss is often permanent. Canadian residents who developed vision loss while taking a GLP-1 medication may have a qualifying claim, subject to individual circumstances.
Severe Gastrointestinal Symptoms
Beyond the named conditions above, some GLP-1 medication users have reported severe gastrointestinal symptoms that required hospitalization, prolonged medical treatment, or led to significant complications.
Common Symptoms
- Severe, persistent nausea requiring IV fluids
- Violent vomiting and inability to tolerate food or liquid
- Severe diarrhea leading to dehydration
- Significant unintended weight loss or malnutrition
- Hospitalization due to GI complications
Connection to GLP-1 Medications
GI symptoms are among the most common reported side effects of GLP-1 medications. While mild nausea is expected, severe or persistent symptoms requiring medical intervention may indicate a more serious adverse reaction.
If you were hospitalized, required significant medical care, or experienced lasting complications due to severe GI symptoms after taking a GLP-1 medication, your situation may qualify for a legal case review.
Did You Experience One of These Side Effects?
If you took a GLP-1 medication and experienced a serious adverse event, you may qualify for a free legal case review. Find out now — it takes about 2 minutes.
- You took Ozempic, Wegovy, or another GLP-1 medication
- You experienced a serious side effect
- You are a resident of Canada
- You have not yet retained a lawyer for this matter
Free case review · No obligation · No upfront fees
Important Legal Notice
GLP-1 Justice is not a law firm and does not provide legal advice. Submitting information through this site does not create an attorney–client relationship. Information submitted may be shared with licensed legal service providers for case review.
The information on this website is provided for general informational purposes only and does not constitute legal advice. No lawyer–client relationship is formed by submitting information through this site or by calling any phone number listed herein.
Individual results vary. Past outcomes are not indicative of future results. Qualifying for a case review does not guarantee a legal claim exists or will succeed. All legal claims are subject to applicable limitation periods and other legal requirements.
This site is intended for residents of Canada only. Services may not be available in all provinces or territories.